Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.

Critically Ill Clinical Trial

Official title:

Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00256048
• Other study ID #: 2002.228
• Status: Completed
• Phase: N/A
• First received: November 17, 2005
• Last updated: April 10, 2017
• Start date: May 2003
• Est. completion date: July 2005

Study information

• Verified date: April 2015
• Source: Melbourne Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if naso-jejunal feeding (feeding beyond the stomach) improves the efficacy of enteral feeding (feeding into the gut) in critically ill patients.

The study hypothesis is that in patients who fail to establish enteral feeding via the nasogastric route, introduction of nasojejunal feeding will lead to more effective enteral feeding than the current regime involving staged introduction of promotility agents.

Description:

The study examines the area of enteral feeding in critically ill patients. Current standard enteral feeding practice is via a nasogastric with the addition of promotility agents for patients who fail to absorb their enteral nutrition.

This study compares the efficacy of nasojejunal feeding feeding with nasogastric enteral feeding with the addition of promotility agents.

The duration of feeding will be determined by the patients nutritional requirements and their general condition. However the data will be collected for duration of enteral feeding, 28 days or ICU discharge whichever occurs first.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult patients (18years or over) admitted to the ICU with an expected stay of more than 48 hours.

2. Patients commenced on enteral feeding via a nasogastric tube who fail to tolerate gastric feeding due to excessive gastric aspirate volumes.

3. Patients who consent or if the patient is incompetent, the next of kin, who consent, to inclusion in the study.

Exclusion Criteria:

1. patients less than 18 years of age.

2. Patients with known allergy to promotility agents, metoclopramide or erythromycin.

3. Patients with a contra indication to nasojejunal feeding. -

Related Conditions & MeSH terms

• Critical Illness
• Critically Ill

Intervention

Procedure:
• Nasojejunal feeding

Locations

Country	Name	City	State
Australia	Intensive Care Unit, Royal Melbourne Hospital, Grattan Street	Parkville	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Melbourne Health

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of feeding		participants will be followed until death, discharge from ICU, commencement of oral or parental nutrition or 28 days post ICU admission
Secondary	1. To determine the incidence of complications with enteral feeding via nasogastric and nasojejunal routes.		participants will be followed until death, discharge from ICU, commencement of parental or oral nutrition or 28 days post ICU admission.
Secondary	2. To assess the efficacy of current strategies for optimising enteral feeding efficacy.		participants will be followed until death, discharge from ICU commencement of oral or parental nutrition,or 28 days post ICU admission.